Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence Testing in Idaho

Andrew Bryan, Gregory Pepper, Mark H. Wener, Susan L. Fink, Chihiro Morishima, Anu Chaudhary, Keith R. Jerome, View ORCID ProfilePatrick C. Mathias, Alexander L. Greninger
doi: https://doi.org/10.1101/2020.04.27.20082362
Andrew Bryan
1Department of Laboratory Medicine, University of Washington School of Medicine, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gregory Pepper
1Department of Laboratory Medicine, University of Washington School of Medicine, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark H. Wener
1Department of Laboratory Medicine, University of Washington School of Medicine, Seattle, WA
2Department of Medicine, University of Washington School of Medicine, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susan L. Fink
1Department of Laboratory Medicine, University of Washington School of Medicine, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chihiro Morishima
1Department of Laboratory Medicine, University of Washington School of Medicine, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anu Chaudhary
1Department of Laboratory Medicine, University of Washington School of Medicine, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Keith R. Jerome
1Department of Laboratory Medicine, University of Washington School of Medicine, Seattle, WA
3Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrick C. Mathias
1Department of Laboratory Medicine, University of Washington School of Medicine, Seattle, WA
4Department of Biomedical Informatics and Medical Education, University of Washington School of Medicine, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Patrick C. Mathias
Alexander L. Greninger
1Department of Laboratory Medicine, University of Washington School of Medicine, Seattle, WA
3Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: agrening@uw.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Coronavirus disease-19 (COVID19), the novel respiratory illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is associated with severe morbidity and mortality. The rollout of diagnostic testing in the United States was slow, leading to numerous cases that were not tested for SARS-CoV-2 in February and March 2020, necessitating the use of serological testing to determine past infections.

Methods We evaluated the Abbott SARS-CoV-2 IgG test for detection of anti-SARS-CoV-2 IgG antibodies by testing 3 distinct patient populations.

Results We tested 1,020 serum specimens collected prior to SARS-CoV-2 circulation in the United States and found one false positive, indicating a specificity of 99.90%. We tested 125 patients who tested RT-PCR positive for SARS-CoV-2 for which 689 excess serum specimens were available and found sensitivity reached 100% at day 17 after symptom onset and day 13 after PCR positivity. Alternative index value thresholds for positivity resulted in 100% sensitivity and 100% specificity in this cohort. We tested 4,856 individuals from Boise, Idaho collected over one week in April 2020 as part of the Crush the Curve initiative and detected 87 positives for a positivity rate of 1.79%.

Conclusions These data demonstrate excellent analytical performance of the Abbott SARS-CoV-2 IgG test as well as the limited circulation of the virus in the western United States. We expect the availability of high-quality serological testing will be a key tool in the fight against SARS-CoV-2.

Competing Interest Statement

ALG has received personal fees from Abbott Molecular, outside of the submitted work.

Funding Statement

This work was funded by the Department of Laboratory Medicine at the University of Washington Medical Center.

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Anonymized data is available upon reasonable request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted May 02, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence Testing in Idaho
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence Testing in Idaho
Andrew Bryan, Gregory Pepper, Mark H. Wener, Susan L. Fink, Chihiro Morishima, Anu Chaudhary, Keith R. Jerome, Patrick C. Mathias, Alexander L. Greninger
medRxiv 2020.04.27.20082362; doi: https://doi.org/10.1101/2020.04.27.20082362
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence Testing in Idaho
Andrew Bryan, Gregory Pepper, Mark H. Wener, Susan L. Fink, Chihiro Morishima, Anu Chaudhary, Keith R. Jerome, Patrick C. Mathias, Alexander L. Greninger
medRxiv 2020.04.27.20082362; doi: https://doi.org/10.1101/2020.04.27.20082362

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (280)
  • Allergy and Immunology (579)
  • Anesthesia (139)
  • Cardiovascular Medicine (1943)
  • Dentistry and Oral Medicine (252)
  • Dermatology (184)
  • Emergency Medicine (333)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (698)
  • Epidemiology (11098)
  • Forensic Medicine (8)
  • Gastroenterology (622)
  • Genetic and Genomic Medicine (3164)
  • Geriatric Medicine (308)
  • Health Economics (561)
  • Health Informatics (2042)
  • Health Policy (862)
  • Health Systems and Quality Improvement (782)
  • Hematology (310)
  • HIV/AIDS (682)
  • Infectious Diseases (except HIV/AIDS) (12714)
  • Intensive Care and Critical Care Medicine (707)
  • Medical Education (317)
  • Medical Ethics (92)
  • Nephrology (334)
  • Neurology (2981)
  • Nursing (164)
  • Nutrition (463)
  • Obstetrics and Gynecology (589)
  • Occupational and Environmental Health (614)
  • Oncology (1549)
  • Ophthalmology (476)
  • Orthopedics (185)
  • Otolaryngology (266)
  • Pain Medicine (202)
  • Palliative Medicine (57)
  • Pathology (402)
  • Pediatrics (912)
  • Pharmacology and Therapeutics (381)
  • Primary Care Research (355)
  • Psychiatry and Clinical Psychology (2782)
  • Public and Global Health (5588)
  • Radiology and Imaging (1092)
  • Rehabilitation Medicine and Physical Therapy (631)
  • Respiratory Medicine (759)
  • Rheumatology (338)
  • Sexual and Reproductive Health (311)
  • Sports Medicine (289)
  • Surgery (343)
  • Toxicology (48)
  • Transplantation (159)
  • Urology (132)